Friday - October 24, 2014

Not intended for U.S. and UK Media

Bayer Forms Alliance with Kyoto University in Japan

Collaboration focuses on areas of high unmet medical need / New Bayer “Open Innovation Center Japan” to support alliance

Leverkusen, October 24, 2014 – Bayer HealthCare and Kyoto University’s Office of Society-Academia Collaboration for Innovation (KU-SACI) have signed a two-year collaboration agreement to jointly identify candidates for possible collaborative research projects. The partners will focus on key areas of worldwide unmet medical need such as cardiology, oncology, hematology, gynecology, and ophthalmology.

This collaboration is part of Bayer’s overall approach to partner with external partners from academia and industry to discover and develop new treatment options for patients worldwide. Recently launched collaborations include for example the strategic research alliance in the area of gynecological therapies with the University of Oxford, UK, or with Dimension Therapeutics for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Furthermore, Bayer has established two research incubators for young life sciences companies in the context of its open innovation approach. Dubbed “CoLaborator” at Bayer’s research and development sites in San Francisco’s Mission Bay, USA, and Berlin, Germany, these research incubators create an ideal environment in which to advance research and innovation.

The agreement with KU-SACI aims at jointly leveraging Kyoto University’s expertise and innovative approaches in diverse research areas and combining it with Bayer’s expertise in drug discovery and development. The endeavor will be supported by Bayer’s newly established “Open Innovation Center Japan” (ICJ) in Osaka, Japan.

About the Office of Society-Academia Collaboration for Innovation, Kyoto University (KU-SACI)
The threefold mission of the Office of Society-Academia Collaboration for Innovation is (1) to promote collaborative research among academia, industries and the government, (2) to manage and utilize the university’s intellectual properties through licensing & research collaboration with industries, and (3) to support business start-ups by university researchers or students. As a result of its recent activities, KU-SACI is scored first or second place among all Japanese universities based on the amount of patent licensing revenue and sponsored research grant from industry.
SACI website: http://www.saci.kyoto-u.ac.jp/en/

About the Bayer Open Innovation Center Japan
The Bayer Open Innovation Center in Japan was launched on June 1, 2014. The ICJ’s main activities are focused on identifying potential collaborative research projects in Japan that explore the mechanisms of diseases related to significant unmet medical needs and to advance the development of innovative therapeutic drugs for those diseases. The ICJ aims at strengthening the company’s network with academic research centers and venture companies in Japan and developing opportunities for joint research and partnering in Bayer’s fields of expertise.
ICJ website https://openinnovation.bayer.co.jp/

About Kyoto University
Kyoto University was founded in 1897 as the second oldest imperial university in Japan. Since that time, Kyoto University has remained faithful to its principle of “academic freedom” and has focused its efforts in developing a strong sense of purpose reflected in its mission statement: “To sustain and develop its historical commitment to academic freedom and pursue a state of harmonious coexistence within the human and ecological community on this planet.” Recognized as one of Japan’s foremost research institutions, the achievements of Kyoto University’s scholars are acknowledged throughout the world. A prominent recent example was the award of the 2012 Nobel Prize in Physiology or Medicine to Dr. Shinya Yamanaka of the Center for iPS Cell Research and Application for his unique discoveries in the field of stem cell research.
Kyoto University’s website: http://www.kyoto-u.ac.jp/en/

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

Our online press service is just a click away: press.healthcare.bayer.com
Follow us on Facebook: http://www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerHealthCare

Find more information at www.bayerpharma.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Download Center


 
0
  file(s) collected
View Download Center
Last updated: January 5, 2016 Copyright © Bayer AG